A5040374936- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Cardiovascular Function and Risk Factors
- Hormonal Regulation and Hypertension
- Potassium and Related Disorders
- Electrolyte and hormonal disorders
- Medication Adherence and Compliance
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Cardiac, Anesthesia and Surgical Outcomes
- Telemedicine and Telehealth Implementation
- Cardiac Arrest and Resuscitation
- Cardiomyopathy and Myosin Studies
- Stuttering Research and Treatment
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Cardiovascular Disease and Adiposity
- MicroRNA in disease regulation
- Acute Myocardial Infarction Research
- Congenital Heart Disease Studies
- Advanced Causal Inference Techniques
- Epilepsy research and treatment
- Ion Transport and Channel Regulation
Amsterdam University Medical Centers
2019-2024
University of Amsterdam
2015-2024
Amsterdam University of Applied Sciences
2024
French Clinical Research Infrastructure Network
2019-2021
Centre d'Investigation Clinique Pierre Drouin
2019-2021
Défaillance Cardiovasculaire Aiguë et Chronique
2019-2021
Université de Lorraine
2018-2020
Inserm
2018-2020
Amsterdam UMC Location University of Amsterdam
2014-2017
Background: The concept of natriuretic peptide guidance has been extensively studied in patients with chronic heart failure (HF), only limited success. effect NT-proBNP (N-terminal probrain peptide)-guided therapy acute decompensated HF using a relative target not investigated. This study aimed to assess whether NT-proBNP-guided would lead improved outcomes compared conventional therapy. Methods: We conducted prospective randomized controlled trial the impact in-hospital for treatment by...
Background We assessed the prognostic significance of absolute and percentage change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels patients hospitalised for acute decompensated heart failure with preservedejection fraction (HFpEF) versus reduced ejection (HFrEF). Methods Patients left ventricular ≥50% were categorised as HFpEF (n=283), while those <40% HFrEF (n=776). Prognostic values NT-proBNP 6 months all-cause mortality after discharge separately by multivariable...
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome for which clear evidence of effective therapies lacking. Understanding factors determine this heterogeneity may be helped by better phenotyping. An unsupervised statistical approach applied to large set biomarkers identify distinct HFpEF phenotypes.Methods: Relevant proteomic were analyzed in 392 patients included Metabolic Road Diastolic HF (MEDIA-DHF). We performed an cluster analysis define...
Abstract Guideline-directed medical therapy (GDMT) has clear benefits on morbidity and mortality in patients with heart failure; however, GDMT use remains low. In the multicenter, open-label, investigator-initiated ADMINISTER trial, ( n = 150) diagnosed failure reduced ejection fraction (HFrEF) were randomized (1:1) to receive usual care or a strategy using digital consults (DCs). DCs contained (1) data sharing from patient clinician (pharmacotherapy use, home-measured vital signs Kansas...
This study compared ways of describing treatment effects. The objective was to better explain clinicians and patients what they might expect from a given treatment, not only in terms relative absolute risk reduction, but also projections long-term survival.The restricted mean survival time (RMST) can be used estimate survival, providing complementary approach more conventional metrics (e.g., risk), which may suggest greater benefits therapy high-risk with low-risk patients.Relative risk, as...
Many patients with heart failure preserved ejection fraction (HFpEF) are women. Exploring mechanisms underlying the sex differences may improve our understanding of pathophysiology HFpEF. Studies focusing on in circulating proteins HFpEF scarce. A total 415 were analyzed 392 included The Metabolic Road to Diastolic Heart Failure: Failure study (MEDIA-DHF). Sex these assessed using adjusted logistic regression analyses. associations between candidate and cardiovascular (CV) death or CV...
Many heart failure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT) despite clear benefit on morbidity and mortality outcomes. Digital consults (DCs) have the potential to improve efficiency GDMT optimization serve growing HF population. The investigator-initiated ADMINISTER trial was designed as a pragmatic multicenter randomized controlled open-label evaluate efficacy safety of DC in treatment.
Abstract Aims Activation of the renin–angiotensin–aldosterone system plays an important role in pathophysiology heart failure (HF) and has been associated with poor prognosis. There are limited data on associations renin aldosterone levels clinical profiles, treatment response, study outcomes patients HF. Methods results We analysed 2,039 available baseline BIOSTAT‐CHF (a systems BIOlogy to Tailored Treatment Chronic Heart Failure). The primary outcome was composite all‐cause mortality or HF...
Background Our aim was to calibrate and externally revalidate the ELAN-HF (European Collaboration on Acute Decompensated Heart Failure) score, confirm improve a previous external validation of risk score. Methods Results The score predicts 6-month all-cause mortality in patients hospitalized for acute decompensated heart failure using absolute percentage change NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels addition clinical variables. For validation, we used PRIMA II (Can...